U.S. Markets closed
  • S&P Futures

    4,340.50
    -1.00 (-0.02%)
     
  • Dow Futures

    34,016.00
    -39.00 (-0.11%)
     
  • Nasdaq Futures

    14,175.00
    +16.50 (+0.12%)
     
  • Russell 2000 Futures

    1,964.60
    -8.10 (-0.41%)
     
  • Crude Oil

    87.18
    -0.17 (-0.19%)
     
  • Gold

    1,819.90
    -9.80 (-0.54%)
     
  • Silver

    23.59
    -0.21 (-0.89%)
     
  • EUR/USD

    1.1237
    -0.0008 (-0.0674%)
     
  • 10-Yr Bond

    1.8480
    +0.0650 (+3.65%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3448
    -0.0014 (-0.1049%)
     
  • USD/JPY

    114.6760
    +0.0160 (+0.0140%)
     
  • BTC-USD

    36,998.79
    +290.79 (+0.79%)
     
  • CMC Crypto 200

    844.52
    -11.29 (-1.32%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,988.96
    -22.37 (-0.08%)
     

Robert Shepler Is The Chairman of the Board of Akoya Biosciences, Inc. (NASDAQ:AKYA) And They Just Picked Up 16% More Shares

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • AKYA

Potential Akoya Biosciences, Inc. (NASDAQ:AKYA) shareholders may wish to note that the Chairman of the Board, Robert Shepler, recently bought US$441k worth of stock, paying US$12.60 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 16%.

See our latest analysis for Akoya Biosciences

The Last 12 Months Of Insider Transactions At Akoya Biosciences

In fact, the recent purchase by Robert Shepler was the biggest purchase of Akoya Biosciences shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$12.89). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

Akoya Biosciences insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Akoya Biosciences is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 5.7% of Akoya Biosciences shares, worth about US$27m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Akoya Biosciences Insider Transactions Indicate?

The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Insiders likely see value in Akoya Biosciences shares, given these transactions (along with notable insider ownership of the company). While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we found 2 warning signs for Akoya Biosciences that deserve your attention before buying any shares.

Of course Akoya Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.